Baxter International Inc. (BAX) is a Medical/Dental Instruments company listed on NYSE. In the last 30 days Quantisnow tracked 7 wire items for BAX, including 2 analyst ratings, 2 earnings updates and 2 SEC filings. The most recent was published Nov 4, 2026.
BAX rankings
Financial highlights
Full financials- Revenue, TTM
- $11.61B
- Revenue growth
- +5.3%
- Net income, TTM
- -$723.00M
- Net margin
- -6.2%
- Cash
- $1.98B
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks340%
2026-05-102026-11-01
Mix1890d
- Insider5(28%)
- SEC Filings4(22%)
- Dividends2(11%)
- Other3(17%)
- Analyst2(11%)
- Earnings2(11%)
Latest news
25 items- FDAFDA Approval for PROPOFOL issued to BAXTER HLTHCARE CORPSubmission status for BAXTER HLTHCARE CORP's drug PROPOFOL (ORIG-1) with active ingredient PROPOFOL has changed to 'Approval' on 11/03/2026. Application Category: ANDA, Application Number: 203421, Application Classification:
- SECSEC Form 10-Q filed by Baxter International Inc.10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- SECSEC Form 8-K filed by Baxter International Inc.8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- PRBaxter Reports Third-Quarter 2026 ResultsThird-quarter sales of $2.98 billion increased 5% on both a reported and organic basis,1, 2 reflecting growth in all segments and divisions Third-quarter U.S. GAAP3 diluted earnings per share (EPS) of $0.57; adjusted diluted EPS of $0.581 Company raises full-year 2026 financial outlook Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2026. "We delivered a strong third quarter, with growth across all segments and divisions globally," said Andrew Hider, president and CEO. "We continue to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement. Our results reinfor
- ANALYSTWolfe Research initiated coverage on BaxterWolfe Research initiated coverage of Baxter with a rating of Peer Perform
- PRBaxter to Host Third-Quarter 2026 Financial Results Conference Call for InvestorsBaxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/analyst/129835310?pwd=2FG2j7ZZ to pre-register for the call and receive the call information.This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter’s permission.About BaxterAt Baxter, we are everywhere healthcare happens – and everywhere it i
- ANALYSTBarclays initiated coverage on Baxter with a new price targetBarclays initiated coverage of Baxter with a rating of Underweight and set a new price target of $20.00
- INSIDERNew insider Rogers Terence John claimed no ownership of stock in the company (SEC Form 3)3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
- PRBaxter Releases Inaugural Connected Hospital ReportExplores how healthcare organizations can maximize the impact of technology investments Introduces a four-stage technology maturity framework to help hospitals benchmark progress and identify areas to prioritize Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the release of its 2026 Connected Hospital Report, offering new insights into how hospitals across the United States are leveraging technology investments to drive clinical and operational outcomes. Based on a survey of 150 information technology (IT) and nursing leaders, the report examines how hospitals are progressing along a "connected hospital" journey by identifying four distinct levels of
- INSIDERNew insider Heine Bernard claimed ownership of 32,840 shares (SEC Form 3)3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
- INSIDERPresident and CEO Hider Andrew P. covered exercise/tax liability with 54,276 shares, decreasing direct ownership by 9% to 518,447 units (SEC Form 4)4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
- INSIDERPresident, CCS Teaff James covered exercise/tax liability with 750 shares, decreasing direct ownership by 2% to 30,370 units (SEC Form 4)4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
- INSIDERPresident, Front Line Care Foster Julie covered exercise/tax liability with 2,098 shares, decreasing direct ownership by 7% to 29,164 units (SEC Form 4)4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
- SECBaxter International Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- PRBaxter Appoints John Rogers Chief Financial OfficerGlobal medtech CFO with broad transformation and leadership experience to help advance Baxter’s turnaround, financial discipline and value creation Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818180217/en/John Rogers, Appointed Baxter CFO "John is a proven global finance executive with extensive operational expertise and a successful track record leadi
- SECBaxter International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- PRBaxter Announces Pricing for Its Upsized Cash Tender OffersBaxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the pricing terms for its previously announced cash tender offers (each, an "Offer" and collectively, the "Offers") of the Company's validly tendered (and not validly withdrawn) notes set forth below (the "Notes") using a "waterfall" methodology under which the Company will accept the Notes in order of their respective acceptance priority levels noted in the table below (the "Acceptance Priority Levels"). The Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026, as amended by the Company’s press release relating to the early tender results and upsizing of the Offers issued on Aug. 18, 2026
- PRBaxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender OffersBaxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the early results of its previously announced cash tender offers (each, an "Offer" and collectively, the "Offers") for its validly tendered (and not validly withdrawn) notes set forth below (collectively, the "Notes"). The Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), which sets forth a description of the terms of the Offers. In addition, the Company has exercised its previously disclosed right to amend the terms of the Offers to increase the aggregate purchase price (excluding accrued and unpaid in
- SECSEC Form 8-K filed by Baxter International Inc.8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- SECBaxter International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- PRBaxter Announces Cash Tender OffersBaxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has commenced cash tender offers (each, an "Offer" and collectively, the "Offers") for the maximum principal amount of validly tendered (and not validly withdrawn) notes set forth below (collectively, the "Notes"), such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million. The terms and conditions of the Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026 (as it may be amended or supplemented from time to time, the "Offer to Purchase"). A summary of the Offers to purchase the Notes is outlin
- ANALYSTBaxter upgraded by Citigroup with a new price targetCitigroup upgraded Baxter from Sell to Neutral and set a new price target of $28.00
- SECSEC Form 10-Q filed by Baxter International Inc.10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- SECBaxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- PRBaxter Reports Second-Quarter 2026 ResultsSecond-quarter sales of $2.96 billion increased 5% on both a reported and organic basis,1, 2 reflecting growth in all segments and divisions Second-quarter U.S. GAAP3 diluted earnings per share (EPS) of $0.26; adjusted diluted EPS of $0.56 Company raises full-year 2026 financial outlook Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2026. "Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance," said Andrew Hider, president and CEO. "While we’re encoura
BAX FAQ
10 questionsWhat does Baxter International Inc. do?
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical...What is the latest news on BAX?
In the last 30 days Quantisnow tracked 7 wire items for BAX: 2 analyst ratings, 2 earnings updates, 2 SEC filings and 1 press release or news item. The most recent was published on November 4, 2026.What is BAX revenue?
Baxter International Inc. (BAX) reported $11.61B of revenue for the twelve months ended Sep 30, 2026. That is up 5.3% from the year before. Revenue for fiscal 2025 was $11.24B.Is BAX profitable?
No. Baxter International Inc. reported a net loss of $723.00M for the twelve months ended Sep 30, 2026.How much cash and debt does BAX have?
Baxter International Inc. reported $1.98B in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does BAX stock trade?
Baxter International Inc. (BAX) is listed on NYSE.What sector and industry is BAX in?
Baxter International Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about BAX?
Across the last 8 analyst actions on Baxter International Inc., there was 1 upgrade and 4 downgrades. The most recent action was from Wolfe Research: Peer Perform on 2026-10-20. Recent price targets range from $17.00 to $42.00.What companies are similar to BAX?
Notable peers in the same industry include JNJ (Johnson & Johnson), MDT (Medtronic plc.), SYK (Stryker Corporation), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company). Compare BAX side-by-side with any of them on Quantisnow.How can I track BAX on Quantisnow?
Quantisnow aggregates Baxter International Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BAX to receive live email and push alerts on every new disclosure.